IP Library Granted Patent US 7,772,275
Granted Patent B2
US 7,772,275 · App. 12/372,535 · Granted Aug 10, 2010

Compositions and method for treating affective, painful or allergic disorders

Assignee: Gideon Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,772,275
App. No.
12/372,535
Granted
Aug 10, 2010
Kind
B2
Abstract

Therapeutic compositions of doxepin and having a preponderance of the cis doxepin isomer over the trans doxepin isomer provide therapeutic effects for affective, painful, or allergic disorders without the sedative effects commonly experienced with compositions having a preponderance of the trans doxepin isomer.

Claims (5)

1. A method of treating affective, painful or allergic disorders in a subject in need thereof, the method comprising treatment with an effective amount of a composition containing a preponderance of cis doxepin isomer over trans doxepin isomer, said cis doxepin isomer being present in an amount of about 0.01% to about 10.0% by weight in a pharmaceutically acceptable vehicle, said composition being comparable in efficacy to compositions containing a preponderance of the trans doxepin isomer but with significantly less sedation and wherein the disorder is selected from the group consisting of atopic dermatitis, allergic rhinitis, and urticaria and the treatment is applying the composition to skin.

2. The method of claim 1 wherein said cis doxepin isomer is present in the amount of about 0.05-5.0% by weight.

3. A method of treating affective, painful, or allergic disorders by oral administration to a subject in need thereof and the treatment comprising an effective amount of a composition containing a preponderance of cis doxepin isomer over trans doxepin isomer, said cis doxepin isomer being present in an amount of about 0.5-500.0 mg per dose or 5 ml portion of liquid in a pharmaceutically acceptable vehicle, said composition being comparable in efficacy to compositions containing a preponderance of trans doxepin isomer but with significantly less sedative side effects and wherein the disorder is selected from the group consisting of atopic dermatitis and urticaria.

4. The method of claim 3 wherein said cis doxepin isomer is present in the amount of about 1.0-50.0 mg per dose.

5. A method of treating allergic conjunctivitis by applying to eyes an effective amount of a composition containing a preponderance of cis doxepin isomer over trans doxepin isomer, wherein said cis doxepin isomer is present in the amount of about 0.05-5.0% by weight.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2023
From: ELORAC, INC.
To: ELORAC CREDITORS TRUST
Reel/Frame 065074/0625 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2011
From: GIDEON PHARMACEUTICALS, INC.
To: ELORAC, INC.
Reel/Frame 026051/0941 →
Continuity (3)
Division 1078125400 · Feb 18, 2004
Continuation 1029440900 · Nov 14, 2002
Related Publication 20090182034A1 · Jul 16, 2009